Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6VR13)

Drug Name
JNJ-69086420 Drug Info
Indication
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM6VR13

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tissue kallikrein (KLK2) TTJLNAW KLK2_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Tissue kallikrein (KLK2) DTT KLK2 2.945 2.807 2.744 3.336
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Prostate cancer
ICD Disease Classification 2C82.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tissue kallikrein (KLK2) DTT KLK2 2.30E-01 -0.02 -0.2
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health.